At a time of intense pressure on health care budgets, the technology management challenge is for disinvestment in low-value technologies and reinvestment in higher value alternatives. The aim of this article is to explore ways in which health economists might begin to redress the observed imbalance between the evaluation of new and existing in-use technologies. The argument is not against evaluating new technologies but in favor of the ''search for efficiency,'' where the ultimate objective is to identify reallocations that improve population health in the face of resource scarcity. We explore why in-use technologies may be of low value and consider how economic evaluation analysts might embrace a broader efficiency lens, first through ''technology management'' (a process of analysis and evidence-informed decision making throughout a technology's life cycle) and progressing through ''pathway management'' (the search for efficiency gains across entire clinical care pathways). A number of model-based examples are used to illustrate the approaches.
P ractitioners of economic evaluation have largely focused narrowly on new technologies, with less emphasis on broader efficiency questions relating to technologies already in widespread use. 1 This ''adoption addiction,'' as it has been referred to elsewhere, 1 has contributed to the unabated rise in health care expenditures over recent years in all developed countries. At a time of intense pressure on health care budgets, the search is for efficiency gains delivered in part through disinvestment in low-value in-use technologies, to facilitate subsequent reinvestment in higher value alternatives.
The aim of this article is to explore how health economists might begin to adopt a broader efficiency lens and redress the observed imbalance between the evaluation of new and in-use technologies. The argument is not against evaluating new technologies-clearly, we need evidence-informed adoption decisions-but in favor of the ''search for efficiency'' (adopting a broad cost-effectiveness lens, with the ultimate objective being to identify reallocations that improve population health in the context of scarce resources).
We first review why in-use technologies may be of low value and consider how economic evaluation analysts might embrace a broader efficiency lens, initially through ''technology management'' and then through analyses of pathways of care. A number of examples are used to illustrate the proposed approaches, and the article concludes with a discussion of opportunities and challenges.
THE VALUE CHALLENGE OF IN-USE TECHNOLOGY
Within any health care system, some low-value technologies are in widespread routine use due to a number of reasons. First, in some jurisdictions, cost or cost-effectiveness evidence is not considered in reimbursement decision making. 2 Second, even where cost-effectiveness evidence is explicitly part of a reimbursement decision-making process, many technologies have been adopted prior to implementation of such value-based approaches. A third explanation for inefficient technology use is indication creep, a process by which a new technology, accepted as beneficial and cost-effective for a specific indication, creeps unevaluated into more widespread use where the value is unproven. 3 Examples include off-label use of various medicines, [3] [4] [5] [6] use of some diagnostic testing, 6 and overuse of certain therapeutic procedures. 7 Fourth, even where technologies are used for approved indications, it is possible that key assumptions, upon which the economic case rests, do not hold up in routine clinical practice. For example, the cost-effectiveness estimates that inform technology adoption decisions typically are heavily influenced by the modeled impact of the technology on the lifetime course of the disease. However, such estimates of relative efficacy are often derived from trials with relatively short patient follow-up. If the assumed extrapolation of longer term benefit fails to materialize in reality, then the predicted cost-effectiveness at the time of adoption may prove unduly optimistic. 8 This reinforces the importance of continuing to monitor a technology's performance after implementation into routine practice. 1, 9, 10 Fifth, the emergence of new, more cost-effective technologies inevitably renders some older technologies as low value, and yet changing practitioner behavior to discontinue use of the older or obsolete technologies can often be challenging. 11, 12 A detailed discussion of the drivers of practitioners' reticence to change clinical practice is out of the scope of this article but, suffice to say, these issues contribute to the ongoing provision of lower value health care.
Finally, in situations where a clinical population is dynamic, with changing demographic distributions and/or risk profiles over time, the costeffectiveness of technologies applied to such populations will likely also vary over time. For example, screening programs for diabetic retinopathy, introduced in many countries based on evidence from studies carried out in the 1970s and 1980s, 13 require ongoing review and reanalysis given the emergence of newer, more effective treatment strategies to improve glycemic control and blood pressure. These newer approaches may have reduced the rate of progression to sight-threatening disease and so improved the health of the population being screened, 14 which may in turn have made universal screening less cost-effective.
Given the likely presence of some significant inefficiencies in current care pathways, our proposition is that health economists be ''searchers for efficiency,'' adopting a broader analytic lens (beyond the focus on adoption questions), to consider efficiency questions relating to both in-use and new technologies. We will now explore how the search for efficiency might be undertaken, initially considering individual technologies (''technology management'') and then widening the canvas to look at multiple technologies across a pathway of care (''pathway management'').
TECHNOLOGY MANAGEMENT
The life cycle of a health technology begins with a research and development stage, and subject to successful early trials, regulatory and reimbursement decision-making hurdles await. Assuming the technology is viewed as safe, effective, and costeffective, it will be available for use in the health care system (the adoption stage). Once in the system, most technologies diffuse, albeit at varying rates, resulting ultimately in widespread use (the in-use stage). Over time, the subsequent development of alternative, superior technologies will typically occur, resulting in a market challenge to the established technology (the withdrawal stage). Technology management is a process of analysis and evidence-informed decision making throughout a technology's life cycle. The adoption decisionmaking stage has been the primary focus for health economists to date and so here we focus on the inuse and withdrawal stages.
The starting point for technology management at the in-use stage is the fact that there are technologies in widespread clinical use, which, for the reasons outlined above, are performing poorly against accepted value criteria. Others have proposed methods for identifying technologies that may fall into this category, which include assessing geographical variation in clinical practice with respect to technology use, 15, 16 engaging with stakeholders and experts to identify potentially obsolete technologies, 17 and using systematic reviews to identify ineffective practices. 18 While these approaches can identify candidate technologies for withdrawal or reconfiguration, such decisions, ultimately, are likely to require more refined evaluative efforts. 19 Technology management can focus this process through asking a series of specific questions:
1. Does a technology, as currently used in practice, deliver value in some or all patients?
2. If yes, how can we ensure widespread implementation of the technology, targeting patients in whom its use represents value? If no, can more cost-effective utilization of the technology be achieved through modification of the clinical protocol?
3. If yes, then changes to the clinical protocol should be made to deliver cost-effective utilization; otherwise, the technology should be withdrawn, freeing up resources for more productive activities.
To demonstrate how the ideas of technology management can be applied, we consider 2 examples: first, screening for diabetic retinopathy and the proposal for risk-stratified screening intervals, and, second, endoscopy performed by nurses in place of physicians.
In 2005, the National Health Service (NHS) in Scotland introduced a national diabetic retinopathy screening program for all individuals with diabetes aged 12 years and older. This adoption decision was based on a health technology assessment and model-based cost-effectiveness analysis that recommended annual screening for all patients using digital retinal photography. 19 The modeling at the adoption stage made use of the best disease progression risk data available at the time, adapted from historical patient cohorts.
However, now the program has been running for several years, a technology management approach speaks to the need for assessment of the ongoing value of the screening program as implemented, as part of a search for system efficiency. The screening outcome data reveal potential for improvement in the design of the screening intervention; it is now clear that many patients with no visible signs of retinopathy face a very low risk of developing referable disease within 1 year. [20] [21] [22] And so the technology management question is, ''Can a more costeffective service be delivered through a risk-stratified approach to screening intervals (i.e., longer intervals between screening episodes for lower risk patients)''? A simulation model, incorporating risks of progression by selected patient characteristics (i.e., current and prior retinopathy screening grades, sex, and type and duration of diabetes) and downstream impacts of timely referral and treatment, was used to assess the impact of moving to biennial screening for low-risk patients, with annual screening maintained for all other patients. 23 The analysis revealed that the change in program design, biennial screening for individuals with no retinopathy observed on 2 consecutive screening episodes, was associated with major cost savings: approximately £11 to £14 million in savings at the national level over a 30-year time horizon. A very small loss in effectiveness was conservatively estimated, giving an incremental cost-effectiveness ratio (ICER) in excess of £200,000 in savings per quality-adjusted life year (QALY) lost. The appropriate technology management recommendation is, therefore, to adapt the screening program, allowing for risk-driven screening intervals.
Our second example of technology management concerns gastrointestinal endoscopy, a well-established and common diagnostic procedure, traditionally performed by physicians. The volume of such procedures has been increasing over time and so, in response to this increasing demand, some health care systems have explored options to reduce unit costs, while maintaining service quality, through nursedelivered endoscopy services. 24 The technology management question, then, is whether efficiency gains result from such a change in service delivery model. This question was explored by Richardson and CHANGING OUR APPROACH TO ECONOMIC EVALUATION IN HEALTH CARE REVIEW others, 24 who undertook an economic evaluation alongside a large pragmatic randomized trial of endoscopy procedures undertaken by nurses rather than by doctors. Unsurprisingly, the cost of care was lower when performed by nurses (by £56,000 per 1000 patients, on average), but the effectiveness was also lower (by 15 QALYs per 1000 patients, on average). When the effectiveness loss is placed alongside the cost saving, the ICER associated with moving from physician to nurse delivery is £3700 in savings per QALY lost. In this case, the saving associated with the change is modest while the loss in QALYs is considerable, and so, based on efficiency considerations alone, the technology management recommendation would be to maintain physician-delivered care. Clearly, workforce considerations and limited access to physician skills may also need to be factored in, and so a decision driven solely by efficiency considerations may be neither possible nor appropriate.
These examples demonstrate the potential allocative efficiency gains from technology management. In the diabetic retinopathy screening case, the opportunity exists to free up resources for reinvestment in potentially higher value technologies, and in the endoscopy example, the technology management process may encourage caution in rolling out a model of nurse delivery.
PATHWAY MANAGEMENT
As a natural extension of technology management, the analyst might adopt a broader frame, searching for efficiency gains across an entire clinical pathway (i.e., pathway management). For example, a single technology might be used at various points in a care management pathway (e.g., a drug therapy for a chronic condition can be used firstline, second-line, or later), and so the pathway management question is which point, if any, represents the most cost-effective option. Clearly, pathways also include a wide range of other clinical interventions and technologies being used at different points in the disease course, and so pathway management would ideally consider technology decisions across the whole disease course. This would see model-based analyses also being used to address questions about the appropriateness and efficiency of other components of the pathway of care (i.e., the sequence of inuse technologies). That is, can further efficiency gains be realized through other changes in the pathway?
By extending the evaluative focus on in-use technologies to consider the entire pathway of care, economic evaluation can potentially help to identify existing low value uses of technology where scope exists for disinvestment and the release of resources for reinvestment in higher value alternative technologies. This is the type of information that decision makers need if they are to make resource allocation decisions that lead to increases in population health in the context of fixed budgets.
The proposition, that efficiency gains are possible through a focus on technology use across a pathway of care, has previously been noted to fit most naturally in the context of broad clinical practice reviews or guideline development processes. 25 The ideas are well illustrated in a recent published example of a whole-disease model. 26 Tappenden and others 26 developed a patient-level simulation model to address a collection of decision problems across the entire clinical guideline pathway for colorectal cancer-ranging from diagnostic and staging questions through to questions on first-and secondline treatments for advanced metastatic disease. The defining feature of their model was that it had sufficient breadth and depth to allow switching of the decision node to address specific questions at different points in the care pathway. With this model, the authors were able to conduct piecewise economic evaluation of 11 of 15 clinical topics identified in a national guideline development process. 27 Importantly, although the model findings were not used to directly inform the clinical guideline, they were able to identify more efficient reallocations of resources within the constraints of the resource envelope for the clinical pathway as a whole. For example, they were able to show that investment in preoperative chemoradiation for resectable rectal cancer, with simultaneous disinvestment in palliative chemotherapy and replacement with a less costly, less effective chemotherapeutic agent, would produce greater overall system QALYs for lower system costs. Ultimately, they were able to illustrate, at least deterministically, a disease-level constrained maximization approach, identifying an optimal service configuration within the clinical pathway, assuming a fixed budget for the clinical pathway.
One of the obvious challenges of whole-disease modeling is the initial time investment required to develop the model, as well as the complexity of the task. Thus, the idea of using whole-disease models (WDMs) to increase our focus on in-use technologies is perhaps a longer term goal-at least in clinical areas where such models do not already exist.
However, there may be scope to embed some of the broader efficiency ideas outlined in the WDM literature in restrictive decision models covering parts of a disease pathway (e.g., those considering the diagnostic and first-line treatment pathways in a specific disease area).
To illustrate how this pragmatic approach might work, let us consider an exploratory analysis from a previous decision modeling exercise to assess the cost-effectiveness of adopting multiparameter (combining T2 and diffusion-weighted) magnetic resonance imaging (mpMRI) as an aid to prostate biopsy in men with suspected prostate cancer. 28 This illustrative example assumes that only those men with a suspicious lesion identified on mpMRI go on to have a targeted transrectal ultrasound (TRUS)guided biopsy and further assumes that false negatives on mpMRI are concentrated in those with localized disease with a low risk of progression. 29 The alternative to mpMRI is a systematic (12-to 14core) TRUS-guided biopsy for all men. Within the model, a number of first-line treatment options were included: radical prostatectomy, external beam radiotherapy, and active surveillance (AS). AS offers men with low-risk disease 29 a chance to delay or avoid aggressive treatment and its associated side effects. It involves regular prostate-specific antigen testing and annual biopsies, with radical treatment indicated following progression but prior to highrisk disease developing. Increasingly, AS is recognized as a viable first-line treatment approach. 30, 31 The mpMRI model considered a distribution of alternative treatment pathways (50% AS and 50% radical treatment), reflecting the current practice in Scotland at the time. 32 Using the model to assess the impact of changes in both diagnostic and downstream treatment pathways, individually and in combination, suggests that potential exists for efficiency gains to be achieved from the more widespread use of AS (Figure 1) . A second policy change, to implement the new more costly and effective diagnostic approach (mpMRI) in addition to AS, may also be supported in this example-subject to appropriate consideration of all the associated uncertainty. 28 In the context of a budget constraint for the clinical pathway as a whole, the savings from the increased use of AS could potentially compensate for the increased cost of adopting the new diagnostic approach.
This example is provided for illustrative purposes, and any policy recommendation to be advised on the back of such a modeling exercise would of course have to be based on a full probabilistic analysis. However, it demonstrates that there is scope within the standard decision modeling framework to explore potential for broader efficiency gains within local clinical pathways. Of course, increased uptake of AS may in reality prove challenging to implement due to physician or patient preference, and so such a policy might require additional resources to promote it, perhaps in the context of a shared decision-making framework. 33 A useful extension to the above analysis could therefore factor in the additional cost of implementation activities and explore potential for the combined pathway changes to be cost-saving/cost-effective within a value of implementation framework. 11 Such a framework could also be used to inform the design of prospective studies to test the hypothesized changes.
A BROADER EFFICIENCY LENS FOR ECONOMIC EVALUATION: THE PROMISE AND THE CHALLENGES
As illustrated in the published colorectal cancer example, the broader search for efficiency can be supported using WMDs that reflect whole clinical pathways. This enables simultaneous evaluation of new technologies for adoption and in-use technologies for possible withdrawal or modification. The prostate cancer example also demonstrates potential for some of the concepts of the broader search for pathway efficiency to be embedded in less comprehensive decision models-that is, by assessing the impact (on costs and outcomes) of introducing a new diagnostic technology (i.e., mpMRI) alone or in combination with changes in the use of existing first-line treatment technologies (e.g., AS v. immediate radical treatments). The process of doing this supports the broader efficiency search, highlighting potential efficiency gains through changes in the current use of technologies (e.g., greater use of AS) in a given disease area. These ideas may be particularly relevant when building models to assess the costeffectiveness of upstream interventions such as screening, diagnostic, or preventive technologies, where it is necessary to model the downstream treatment pathways. Modeling has the additional advantage that it also provides the opportunity to consider 2 or more practice changes simultaneously and to assess the efficiency implications of each change separately as well as in combination.
A particular challenge when applying modelbased methods in broader efficiency searching, to evaluate in-use technologies and pathways, is data availability. Much of current practice has not been subjected to clinical trials, and even if practice has a strong evidence base, it will likely be quite old. Therefore, some model parameter inputs are likely to be missing or less certain. For example, the effect difference between an in-use intervention and appropriate comparator is likely to be a challenge to estimate precisely, and similarly on the cost side, the incremental cost will be uncertain in the absence of recent trial evidence. Alternative approaches to estimating the incremental effect and cost include use of observational data with appropriate adjustment to guard against potential bias. 34, 35 It is important also to note that, increasingly, Health Technology Assessment (HTA) agencies are recognizing the need to evaluate in-use procedures that have crept unevaluated into widespread use, and so more prospective trials are likely to be commissioned, offering the potential to assess the cost-effectiveness of in-use technologies using prospectively collected data. 36, 37 Finally, even if data limitations are identified prior to or during the modeling process, this should not be used as a block on subjecting in-use technologies to rigorous assessment. 38, 39 Karnon and others 39 argue that the evaluation process will highlight uncertainties and limitations in the evidence and potentially inform the need for further primary data collection to reduce the uncertainty surrounding decisions to modify or withdraw in-use technologies.
Supposing the move away from adoption-focused analyses toward broader efficiency searches is seen as desirable, what might this require in terms of organization and resources? Probably the most appropriate starting point would be to use models developed to assess diagnostic/screening technologies, given that such models have, by necessity, considered both diagnosis and treatment pathways. The efficiency search might then begin by examining concurrently the cost-effectiveness of in-use first-line treatments. This would require formal consideration of the comparative effectiveness of alternative treatments (ideally exploring heterogeneity in effectiveness, possibly through the use of subgroups) and also examination of how they are currently implemented based on up-to-date observational data. If data allow, analysts might then compare the current set of active interventions with more conservative approaches (e.g., watchful waiting). Such a framework sets the scene for assessing the cost-effectiveness of the current first-line treatment strategies, as well as combinations of different diagnostic/treatment strategies.
A further step in this direction, and perhaps the ultimate destination, is the realm of WDMs, or at least models that reflect whole clinical pathways. Several commentators have previously proposed and demonstrated comprehensive modeling approaches capable of examining resource reallocations involving simultaneous investments and disinvestments within whole-disease pathways 26, 40, 41 or even across disease pathways. 42 Tappenden and others 40 have proposed a WDM framework and, as discussed above, demonstrated its application in the area of colorectal cancer. 26 They describe WDMs as being broad in scope, covering the whole-disease pathway from prediagnosis to end-stage disease, as well as all the interventions that are currently provided. A defining feature of what they propose is that such models should also have sufficient depth and detail to allow switching of the decision node to examine questions at different points in the care pathway, providing a means to identify efficient reallocations of resources. This is important since standard economic evaluation, which fixes the decision to be at a specific point in the disease pathway (e.g., the choice between firstline treatments), will fail to ascertain how, for example, a change in the approach to first-line treatment might affect the cost-effectiveness of interventions at other points in the pathway (e.g., screening or approaches to diagnosis) or vice versa. Similarly, Lord and others 41 have explored the challenges around implementing whole clinical pathway models in the context of guidelines development in the areas of prostate cancer and atrial fibrillation. Further wholedisease/reference models have been developed over the years in clinical areas, including diabetes, 43, 44 cardiovascular disease, 45 and cancer, 46 where they have been successfully used to address numerous decision problems over time. [47] [48] [49] [50] [51] This also has the advantage that it brings a degree of consistency to the evaluation process that is often lacking in adoption-focused piecewise economic evaluation.
DISCUSSION AND CONCLUSIONS
This article has considered two ways in which health economic analysts might seek to redress the observed imbalance between the evaluation of new technologies for adoption and existing technologies that might not be providing value in routine use. One is simply to increase the focus of standard piecewise assessments of cost-effectiveness on technologies that are in widespread routine use, where there is reason to believe that these technologies might not be providing value at accepted standards of value based adoption decision making. Such assessments might rely on use of observational data to inform certain key model parameters such as progression rates or disease survival, or where trials of less costly and more conservative approaches to care have been funded, these can be prospective and based on randomized data. Such efforts will have to recognize the heterogeneity in patient populations and the fact there may be few interventions that are candidates for complete withdrawal. Rather, it may be more likely that many interventions are cost-effective for some of the current recipients but not for others. Thus, a more stratified approach to evaluating in-use technologies, with an emphasis on informing marginal disinvestment, may be more appropriate. In the diabetic retinopathy example described above, it was originally an analysis of observational data on baseline progression risks that pointed to potential for improving efficiency in screening provision. Equally, as data for comparative effectiveness become more widely available through, for example, ongoing trials, individual patient data IPD meta-analysis would offer greater power to identify treatment effect modifiers and so facilitate a more stratified approach to assessing the cost-effectiveness of in-use technologies.
The second way in which the health economics community can increase the focus of economic evaluation on in-use technologies, and so promote a broader search for allocative efficiency, is to adopt a broader clinical pathway perspective in evaluative efforts. What we are advocating in this article is generally aligned with the broader efficiency objectives of whole-disease/pathway modeling. However, given the extensive analytic resource required, it seems unlikely that this approach will be routinely feasible for many disease areas in the near future. Therefore, we are arguing that some of the broader efficiency objectives of whole-disease modeling can be incorporated in relatively simple models developed with a technology adoption focus. That said, complexity is not, in itself, a strong argument against WDMs, and so we support this where it is already feasible and as a longer term objective in clinical areas where it currently is not.
Over and above the analytic challenge of developing a WDM, there are ongoing resource requirements relating to maintenance and updating, to ensure that the WDM remains useful and relevant. This ongoing need for modeling resources will be particularly pertinent in dynamic clinical areas where new therapies are being introduced and alterations made to care pathways. Developers of WDMs may also be reluctant to release their models to protect their investment, wishing to maximize the return and guard against inappropriate modification and use. Conversely, users are likely to want WDMs that can be easily modified to meet their local needs, at a low analytic cost. Aligning these potentially competing incentives is not straightforward, but the challenge must be addressed if WDMs are to be used widely to improve system-level efficiency.
If health economists and HTA practitioners are to embrace a broader search for efficiency, it will also be important to consider possible changes in the skill mix and organization of HTA research groups. The need is to organize around disease areas and embrace a more iterative approach, all in pursuit of more comprehensive models. To produce actionable recommendations in relation to in-use technologies, health economists and modelers will need to collaborate closely with clinical teams and decision makers. This can be framed as integrated knowledge translation (KT), nurturing a shared responsibility for the specification of the decision problem and model development, with the ambition of increasing policy impact (http://www.cihr-irsc.gc.ca/e/ 45321.html).
The adoption of an integrated KT approach fosters notions of resource stewardship responsibility among clinical teams, with explicit consideration of resource constraints across the care pathway. Potentially, this will help to identify areas where opportunities exist to achieve better value from changes in the provision of in-use technologies, as well as questions relating to the introduction of new technologies. Framing these questions collaboratively at the outset increases the likelihood of producing recommendations that promote the broader search for efficiency and, hence, meet the needs of decision makers. Our contention is that broader searches for efficiency can begin now using existing decision modeling methods and should not be conditional upon development of comprehensive WDMs.
In conclusion, we encourage the health economics and the HTA community to embrace the role of ''searchers for efficiency'' rather than technology evaluators. This would involve a rejection of the current, almost exclusive, emphasis on technology adoption and the replacement of that with a broader analytic frame to consider clinical pathways and ultimately whole diseases. This broadening of the analytic scope offers the possibility of fundamentally changing the nature of the contribution we can make to resource allocation decision making.
